SCHEMBL25213243

SCHEMBL25213243

COC(=O)c1cnc(-c2ccccc2)cn1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.49
▸ GAA P10253 1/20 0.49
▸ MAPK1 P28482 2/20 0.49
▸ KDM4E B2RXH2 4/20 0.48
▸ ALDH1A1 P00352 3/20 0.48
▸ HPGD P15428 2/20 0.48
▸ HSD17B10 Q99714 2/20 0.48
▸ BAZ2B Q9UIF8 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ CYP3A4 P08684 2/20 0.46
▸ GABRG2 P18507 2/20 0.46
▸ GABRB3 P28472 2/20 0.46
▸ GABRA5 P31644 2/20 0.46
▸ GABRA3 P34903 2/20 0.46
▸ LDHA P00338 2/20 0.45
▸ GABRP O00591 1/20 0.44
▸ GABRD O14764 1/20 0.44
▸ PDE5A O76074 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14022401 0.85 RAB9A (0.50) MEN1KMT2ATDP1MAPK1KDM4E
SCHEMBL24994318 0.84 RXFP1 (0.54) KMT2AMAPK1KDM4EALDH1A1HPGD
SCHEMBL5305431 0.81 LDHA (0.49) MEN1KMT2ATDP1ALDH1A1HPGD
SCHEMBL2929188 0.80 LDHA (0.56) KDM4EALDH1A1HPGDHSD17B10BAZ2B
SCHEMBL1549552 0.80 CFTR (0.44) KMT2AMAPK1KDM4EALDH1A1HPGD
SCHEMBL23309287 0.80 CYP4F2 (0.48) —
SCHEMBL68869 0.80 MAPK1 (0.63) MAPK1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL5309386 0.79 CYP3A4 (0.55) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL10328675 0.78 KDM4E (0.50) MAPK1KDM4EALDH1A1L3MBTL1LMNA
SCHEMBL5309392 0.78 OXTR (0.46) MEN1KMT2ATDP1BAZ2BCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260083851-A1 POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS AVILAR THERAPEUTICS, INC. (US) 2026-03-26 — — US disclosed
WO-2025085347-A1 IL4I1 INHIBITORS AND USES THEREOF MERCK SHARP & DOHME LLC (US) 2025-04-24 — — WO disclosed
WO-2024098039-A2 POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-05-10 — — WO disclosed
WO-2023097386-A1 SELECTIVE HDAC6-INHIBITING N-ACYLHYDRAZONE COMPOUNDS, METHODS FOR PRODUCING SAME, COMPOSITIONS, USES, TREATMENT METHODS AND KITS EUROFARMA LABORATÓRIOS S.A (BR) 2023-06-08 — — WO disclosed
WO-2023097386-A1 SELECTIVE HDAC6-INHIBITING N-ACYLHYDRAZONE COMPOUNDS, METHODS FOR PRODUCING SAME, COMPOSITIONS, USES, TREATMENT METHODS AND KITS EUROFARMA LABORATÓRIOS S.A (BR) 2023-06-08 — — WO disclosed
CN-115181092-A Pyrazine compounds and uses thereof 迪哲(江苏)医药股份有限公司 2022-10-14 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260083851-A1 POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS ASGR1, FCGR2A, FCGR3B MEN1 4703/4885KMT2A 4453/4885TDP1 4344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback